Clinical analysis of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamases in patients with respiratory tract infection

朱惠莉,王亚岚,周伊南,龚瑾

DOI: https://doi.org/10.3969/j.issn.1001-8689.2001.03.008

2001-01-01

Abstract:Objective: To investigate the antibiotic resistance of strains producing ESBLs among Klebsiella pneumoniae and Escherichia coli in patients with respiratory tract infection, and the prognosis of these patients. Methods: 92 strains of Klebsiella pneumoniae and Escherichia coli in 78 patients with respiratory tract infection were analysed; 16 strains of ESBLs-producing E. coli and 28 strains of ESBLs-producing K. pneumoniae were determined by Vitet method and antibiotic susceptibility test. The prognosis and relationship between antibiotics used and ESBLs producing ones were evaluated. Results: The prevalence of ESBLs in isolates of 59 K. pneumoniae was 47.5% and E. coli 48.5% respectively. The resistant rate of ESBLs-producing strains to aminoglycosides (except amikacin), quinolones, cephalosporins and ampicillin was higher than that of non ESBLs-producing strains. ESBLs-producing strains had higher resistant rate to aminoglycosides (except amikacin), quinolones, second and third-generation cephalosporins and ampicillin, but few of which was resistant to imipenem and amikacin. The susceptibility rate of these strains to sulfonamides and cefoxitin was about 37.5%∼50%. The mortality of patients with respiratory tract infection of ESBLs-producing strain was higher. Conclusion: The results indicated that such antibiotics as imipenem, amikacin, sulfonamides, cefoxitin and others which are susceptible to ESBLs-producing strain can be used. The prognosis of patients with respiratory tract infection of ESBLs-producing strain was poor. The unreasonable using of antibiotics may lead to the spread of ESBLs-producing strain.